Background: Despite an increase in the number of therapies available to treat patients with
immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist …

Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low
platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated …

Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in variable
bleeding symptoms and thrombocytopenia. In the last decade, changes in our …

Platelets are anucleate cells that are crucial mediators of haemostasis. Most immunologists
probably don't think about platelets every day, and may even consider these cells to …

Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by
autoantibodies against platelet GPIIbIIIa and/or the GPIb complex. Current theory suggests …

Immune thrombocytopenia (ITP) is an autoimmune disease defined by low platelet counts
which presents with an increased bleeding risk. Several genetic risk factors (eg …

The epidemiology of immune thrombocytopenia (ITP) is not well known. The purpose of this
study was to assess ITP incidence at a nationwide level (France) with recent data (mid-2009 …

Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …

Splenectomy is an effective therapy for steroid-refractory or dependent immune
thrombocytopenia (ITP). With the advent of medical alternatives such as rituximab and …

Monoclonal B lymphocytosis (MBL) is defined as the presence of a clonal B-cell population
in the peripheral blood with fewer than 5× 109/L B-cells and no other signs of a …